119 related articles for article (PubMed ID: 26038994)
1. [Financial burden of hepatitis C infection and its treatment].
Makara M; Hunyady B
Orv Hetil; 2015 May; 156(21):862-8. PubMed ID: 26038994
[TBL] [Abstract][Full Text] [Related]
2. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
3. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
[TBL] [Abstract][Full Text] [Related]
4. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
5. An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Rubin A; Berenguer M
Liver Transpl; 2010 Jun; 16(6):697-700. PubMed ID: 20517902
[No Abstract] [Full Text] [Related]
6. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
7. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867
[TBL] [Abstract][Full Text] [Related]
8. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 22 September 2017].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2018 Feb; 159(Suppl 1):3-23. PubMed ID: 29478339
[TBL] [Abstract][Full Text] [Related]
9. [Editorial commentary: Hepatitis C].
Pár A
Orv Hetil; 2015 May; 156(21):835. PubMed ID: 26038989
[No Abstract] [Full Text] [Related]
10. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156 Suppl 1():3-23. PubMed ID: 26039413
[TBL] [Abstract][Full Text] [Related]
11. [Not Available].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Dec; 156 Suppl 2():3-24. PubMed ID: 26667111
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
J Viral Hepat; 2010 Jan; 17(1):34-50. PubMed ID: 19656290
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
14. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
[TBL] [Abstract][Full Text] [Related]
15. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C.
Gao X; Stephens JM; Carter JA; Haider S; Rustgi VK
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):335-43. PubMed ID: 22812557
[TBL] [Abstract][Full Text] [Related]
16. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2004 Sep; 23(3):261-72. PubMed ID: 15370005
[TBL] [Abstract][Full Text] [Related]
17. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
18. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?
Saab S; Ly D; Han SB; Lin RK; Rojter SE; Ghobrial RM; Busuttil RW
Liver Transpl; 2002 May; 8(5):449-57. PubMed ID: 12004345
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
20. [Medico-economic assessment of the therapeutic management of patients with hepatitis C].
Loubière S; Rotily M; Moatti JP
Gastroenterol Clin Biol; 2000 Nov; 24(11):1047-51. PubMed ID: 11139674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]